Non-lipid properties of statins
M. J. Kendall,
V. Toescu,
M. J. Kendall
Clinical Pharmacology Section, Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, U.K.
Search for more papers by this authorV. Toescu
Clinical Pharmacology Section, Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, U.K.
Search for more papers by this authorM. J. Kendall,
V. Toescu,
M. J. Kendall
Clinical Pharmacology Section, Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, U.K.
Search for more papers by this authorV. Toescu
Clinical Pharmacology Section, Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, U.K.
Search for more papers by this author
Kendall
M. J.
Tel: + 44 (0)121 414 6874;fax: + 44 (0)121 414 1355; e-mail: [email protected]
No abstract is available for this article.
References
- Kendall, MJ, Horton RC, ed. (1998) Preventing Coronary Artery Disease. 2nd edn. Martin Dunitz, London.
- Gorden T, Castelli WP, Hjortland MC. (1977) High lipoprotein as a protective factor against coronary heart disease: The Framingham Study. American Journal of Medicine, 62, 707-714.
- Hebert P, Gaziano M, Chan KS, Hennekens CH. (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. Journal of the American Medical Association, 278, 313-321.
- West of Scotland Coronary Prevention Study Group. (1998) Influence of Pravastain and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 97, 1440-1445.
- Scandinavian Simvastatin Survival Study Group. (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
- Sacks F, Rouleau J, Moye LA, et al . (1995) Baseline characteristic in the cholesterol and recurrent events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. American Journal of Cardiology, 75, 621-623.
- The Lipid Study Group. (1995) Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. American Journal of Cardiology, 76, 474-479.
- Sacks F, Pfeffer M, Moye L, et al . (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine, 335, 1001-1009.
- Muldoon MF, Criqui MH. (1997) The emerging role of statins in the prevention of coronary heart disease. British Medical Journal, 315, 1554-1555.
- Vaughan CJ, Murphy MB, Buckley BM. (1996) Statins do more than just lower cholesterol. Lancet, 348, 1079-1082.
- Rosenson RS, Tangney CC. (1998) Antiatherothrombotic properties of statins. Journal of the American Medical Association, 279, 1643-1650.
- Schatner M. (1995) Lipid lowering and the arterial wall. British Journal of Cardiology, 2Suppl., S22-S24.
- Horton R. (1994) Reversing risk in coronary disease. Lancet, 344, 1497-1498.
- Keidar D, Aviram M, Maor I, Oiknine J, Brook JG. (1994) Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. British Journal of Clinical Pharmacology, 38, 513-519.
- Hunt BJ, Jurd KM. (1998) Endothelial cell activation. British Medical Journal, 316, 1328-1329.
- Egashira K, Hirooka Y, Kai H, et al . (1994) Reductions in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation, 89, 2518-2524.
- Williams JK, Sukhova GK, Herrington DM, Libby P. (1998) Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. Journal of the American College of Cardiology, 31, 684-691.
- Weissberg PL, Clesham GJ, Bennett MR. (1996) Is vascular smooth muscle cell proliferation beneficial Lancet, 347, 305-307.
- Carvalho AC, Colman RW, Less RS. (1974) Platelet function in hyperlipoproteinemia. New England Journal of Medicine, 290, 434-438.
-
Lacoste L,
Lam JYT. (1996)
Comparative effects of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients.
Journal of the American College of Cardiology, 27, 413A.
10.1016/S0735-1097(96)82590-3 Google Scholar
- The LIPID Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339, 1349-1357.
